Small molecule · Antagonist of C-C chemokine receptor type 4 (CCR4) · developed by RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Tivumecirnon is an orally available small molecule that antagonizes the chemokine receptor CCR4, inhibiting its binding to signaling molecules. By blocking CCR4, it is intended to prevent regulatory T-cells from being recruited to the tumor microenvironment. It is being studied in advanced cancer and advanced melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04894994 | Phase 2 | Advanced Melanoma | Terminated | GSK |
| NCT03674567 | Phase 1/2 | Advanced Cancer | Completed | GSK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerAdvanced Melanoma
See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
GSK catalysts and pipeline →